Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016
Published Jun 08, 2016
87 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016, provides an overview of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
- The report reviews pipeline therapeutics for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) therapeutics and enlists all their major and minor projects
- The report assesses Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
- Identify potential new clients or partners in the target demographic
- Develop strategic

  
Source:
Document ID
GMDHC8194IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Overview81
Therapeutics Development92
  Pipeline Products for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Overview91
  Pipeline Products for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Comparative Analysis101
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics under Development by Companies111
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics under Investigation by Universities/Institutes121
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Pipeline Products Glance133
  Clinical Stage Products131
  Early Stage Products141
  Unknown Stage Products151
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Products under Development by Companies161
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Products under Investigation by Universities/Institutes171
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Companies Involved in Therapeutics Development1810
  AngioChem Inc.181
  ArmaGen Inc.191
  Athersys, Inc.201
  Bioasis Technologies Inc.211
  Eloxx Pharmaceuticals, Ltd.221
  Inventiva231
  OPKO Health, Inc.241
  PTC Therapeutics, Inc.251
  RegenxBio Inc.261
  Sangamo BioSciences, Inc.271
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Assessment289
  Assessment by Monotherapy Products281
  Assessment by Target292
  Assessment by Mechanism of Action312
  Assessment by Route of Administration332
  Assessment by Molecule Type352
Drug Profiles3736
  AGT-181 Drug Profile372
  ataluren Drug Profile398
  Cell Therapy for Mucopolysaccharidosis I Drug Profile472
  Cell Therapy to Activate Iduronidase for Hurler Syndrome Drug Profile491
  odiparcil Drug Profile501
  Oligonucleotide for Mucopolysaccharidosis I Drug Profile511
  pentosan polysulfate sodium Drug Profile521
  PF-05285401 Drug Profile5311
  Recombinant Alpha-L-Iduronidase Replacement for Hurler Syndrome Drug Profile641
  Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I Drug Profile651
  Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I Drug Profile661
  RGX-111 Drug Profile672
  SB-318 Drug Profile692
  Small Molecules for Hurler Syndrome Drug Profile711
  Stem Cell Therapy for Type1 Mucopolysaccharidosis Drug Profile721
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Dormant Projects731
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Discontinued Products741
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Product Development Milestones7511
  Featured News &Press Releases751
    May 09, 2016: Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic Programs In Multiple Presentations At Annual Meeting of the American Society of Gene and Cell Therapy752
    Mar 31, 2016: ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome771
    Feb 08, 2016: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I781
    Dec 30, 2015: FDA Grants Rare Pediatric Disease Designation to REGENXBIO RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)791
    Nov 05, 2015: ArmaGen Receives Rare Pediatric Disease Designation from FDA for AGT-181 for the Potential Treatment of Hurler Syndrome791
    Oct 01, 2015: FDA Grants Orphan Drug Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I801
    Sep 02, 2015: ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome801
    Apr 08, 2015: ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome811
    Dec 19, 2014: Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I811
    Feb 05, 2014: Mouse Study Shows Gene Therapy May Be Possible Cure for Hurler Syndrome821
    Jul 10, 2012: Athersys Receives Orphan Drug Designation For MultiStem In Hurler s Syndrome831
    Apr 20, 2012: Athersys Announces Publication Of Results Of Preclinical Study Of MultiStem In Cell Transplant842
Appendix862
  Methodology861
  Coverage861
  Secondary Research861
  Primary Research861
  Expert Panel Validation861
  Contact Us861
  Disclaimer871

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mucopolysaccharidosis-I-MPS-I-Hurler-Syndrome-Pipeline-Review-H1-2016-2088-15922>
  
APA:
Global Markets Direct - Market Research. (2016). Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mucopolysaccharidosis-I-MPS-I-Hurler-Syndrome-Pipeline-Review-H1-2016-2088-15922>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.